Picture loading failed.

Pre-Made Atibuclimab biosimilar, Whole Mab: Anti-CD14 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Atibuclimab (formerly IC 14) is a recombinant chimeric monoclonal antibody being developed by Implicit Bioscience for the treatment of acute lung injury, motor.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-035-1mg 1mg 3090
GMP-Bios-ab-035-10mg 10mg Inquiry
GMP-Bios-ab-035-100mg 100mg Inquiry
GMP-Bios-ab-035-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Atibuclimab biosimilar, Whole Mab: Anti-CD14 therapeutic antibody
INN Name Atibuclimab
TargetCD14
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2020
Year Recommendedna
CompaniesICOS Corporation;Implicit Bioscience
Conditions Approvedna
Conditions ActiveAcute lung injury;COVID-19
Conditions DiscontinuedAdult respiratory distress syndrome;Motor neuron disease;Septic shock
Development Techna